Bristlecone Advisors LLC Purchases 2,395 Shares of Novo Nordisk A/S (NYSE:NVO)

Bristlecone Advisors LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 24.2% during the fourth quarter, Holdings Channel reports. The fund owned 12,293 shares of the company’s stock after acquiring an additional 2,395 shares during the period. Bristlecone Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,057,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of NVO. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $42,000. Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $48,000. Dunhill Financial LLC lifted its position in shares of Novo Nordisk A/S by 196.8% during the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after buying an additional 311 shares in the last quarter. Finally, Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $83.90 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The stock’s 50 day simple moving average is $91.46 and its two-hundred day simple moving average is $111.21. The company has a market cap of $376.48 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.